Search

Your search keyword '"Horng, Chuan‐Sheng"' showing total 10 results
Start Over Author "Horng, Chuan‐Sheng"
10 results on '"Horng, Chuan‐Sheng"'

2. Abstract 12767: Sodium-Glucose Cotransporter-2 Inhibitors Are Associated With Lower Risks of Hospitalization for Heart Failure and All-Cause Mortality in Patients With Diabetes Mellitus and Cancer

Author

Chiang, Cho Han, CHIANG, CHO HUNG, Chiang, Cho Hsien, Ma, Kevin, Peng, Chun-Yu, yuanping, HSIA, Horng, Chuan-Sheng, CHEN, CHENG-YING, Chang, Yu-Cheng, See, Xin Ya, Chen, Yuan-Jen, Wang, Shih-Syuan, Suero Abreu, Giselle A, Peterson, Linda R, Thavendiranathan, Paaladinesh, Armand, Philippe, Peng, Cheng-Ming, Shiah, Her-Shyong, and Neilan, Tomas G

Published
2022
Full Text
View/download PDF

3. The impact of sodium‐glucose cotransporter‐2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer

Author

Chiang, Cho‐Han, primary, Chiang, Cho‐Hung, additional, Hsia, Yuan Ping, additional, Jaroenlapnopparat, Aunchalee, additional, Horng, Chuan‐Sheng, additional, Wong, Kit Yee, additional, Wang, Shih‐Syuan, additional, Chang, Yu‐Cheng, additional, Chen, Brian Shiian, additional, Luan, Yu‐Ze, additional, Wang, Chun‐Hao, additional, Neilan, Tomas G., additional, Chiang, Cho‐Hsien, additional, Peng, Cheng‐Ming, additional, and Shiah, Her‐Shyong, additional

Published
2024
Full Text
View/download PDF

4. Efficacy of Lipophilic Statins on Outcomes of Patients Treated with Immune Checkpoint Inhibitors.

Author

Chiang, Cho-Han, Chen, Yuan-Jen, See, Xin Ya, Chang, Yu-Cheng, Wang, Shih-Syuan, Peng, Chun-Yu, Horng, Chuan-Sheng, Hsia, Yuan Ping, Chiang, Cho-Hung, Peng, Cheng-Ming, and Chiang, Cho-Hsien

Subjects
STATINS (Cardiovascular agents), DRUG efficacy, DISEASE progression, IMMUNE checkpoint inhibitors, ANTILIPEMIC agents, ACADEMIC medical centers, MORTALITY, RETROSPECTIVE studies, TREATMENT effectiveness, DESCRIPTIVE statistics, PROGRESSION-free survival, DATA analysis software, HEPATOCELLULAR carcinoma, IMMUNOTHERAPY, LONGITUDINAL method, OVERALL survival, PROPORTIONAL hazards models, EVALUATION
Abstract

Background: Statins are associated with improved survival outcomes in patients receiving immune checkpoint inhibitors (ICIs), but the impact of lipophilic and hydrophilic statin properties on patient outcomes is unknown. Objectives: We aim to investigate if statins with lipophilic properties are associated with clinical outcomes in patients receiving ICIs. Method: We conducted a retrospective cohort study at two tertiary referral centers in Taiwan comprising patients receiving ICIs between January 2015 and December 2021. We compared the comparative effect of lipophilic and hydrophilic statins on patient outcomes. The primary outcome was overall survival (OS) and the secondary outcome was progression-free survival (PFS). Results: Among 734 patients receiving ICIs, there were 51 lipophilic statin users, 25 hydrophilic statin users, and 658 nonusers. Lipophilic statin users had a longer median OS (38.0 [IQR, 16.7–not reached] vs. 15.2 [IQR, 8.2–not reached] months vs. 18.9 [IQR, 5.4 51.6] months) and PFS (13.0 [IQR, 4.7–41.5] vs. 8.2 [IQR, 2.2–14.7] months vs. 5.6 [2.3–18.7] months) than hydrophilic statin users and non-statin users. In Cox proportional hazard analyses, the use of lipophilic statins was associated with a 40–50% lower risk of mortality and disease progression compared with hydrophilic statin or non-statin users. Conclusions: The use of lipophilic statins seems to be associated with survival benefits in patients undergoing immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

5. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer

Author

Chiang, Cho-Han, primary, Chiang, Cho-Hung, additional, Chiang, Cho-Hsien, additional, Ma, Kevin Sheng-Kai, additional, Peng, Chun-Yu, additional, Hsia, Yuan Ping, additional, Horng, Chuan-Sheng, additional, Chen, Cheng-Ying, additional, Chang, Yu-Cheng, additional, See, Xin Ya, additional, Chen, Yuan-Jen, additional, Wang, Shih-Syuan, additional, Suero-Abreu, Giselle A, additional, Peterson, LR, additional, Thavendiranathan, Paaladinesh, additional, Armand, Philippe, additional, Peng, Cheng-Ming, additional, Shiah, Her-Shyong, additional, and Neilan, Tomas G, additional

Published
2022
Full Text
View/download PDF

6. Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors

Author

Chiang, Cho-Han, primary, Chiang, Cho-Hung, additional, Peng, Chun-Yu, additional, Hsia, Yuan Ping, additional, See, Xin Ya, additional, Horng, Chuan-Sheng, additional, Chang, Yu-Cheng, additional, Shen, Xuan-Er, additional, Wang, Shih-Syuan, additional, Tsai, Tien-Chi, additional, Chen, Yuan-Jen, additional, Ma, Kevin Sheng-Kai, additional, Chen, Brian Shiian, additional, Luan, Yu-Ze, additional, Tay, Soon-Tzeh, additional, Shen, Chin-Hsuan, additional, Chung, Katharine Ching, additional, Chiang, Cho-Hsien, additional, and Peng, Cheng-Ming, additional

Published
2022
Full Text
View/download PDF

7. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer

Author

Chiang, Cho-Han, Chiang, Cho-Hung, Chiang, Cho-Hsien, Ma, Kevin Sheng-Kai, Peng, Chun-Yu, Hsia, Yuan Ping, Horng, Chuan-Sheng, Chen, Cheng-Ying, Chang, Yu-Cheng, See, Xin Ya, Chen, Yuan-Jen, Wang, Shih-Syuan, Suero-Abreu, Giselle A, Peterson, LR, Thavendiranathan, Paaladinesh, Armand, Philippe, Peng, Cheng-Ming, Shiah, Her-Shyong, and Neilan, Tomas G

Abstract

ObjectivesSodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce heart failure (HF) in at-risk patients and may possess antitumour effects. We examined the effect of SGLT2i on HF and mortality among patients with cancer and diabetes.MethodsThis was a retrospective propensity score-matched cohort study involving adult patients with type 2 diabetes mellitus diagnosed with cancer between January 2010 and December 2021. The primary outcomes were hospitalisation for incident HF and all-cause mortality. The secondary outcomes were serious adverse events associated with SGLT2i.ResultsFrom a total of 8640 patients, 878 SGLT2i recipients were matched to non-recipients. During a median follow-up of 18.8 months, SGLT2i recipients had a threefold lower rate of hospitalisation for incident HF compared with non-SGLT2i recipients (2.92 vs 8.95 per 1000 patient-years, p=0.018). In Cox regression and competing regression models, SGLT2i were associated with a 72% reduction in the risk of hospitalisation for HF (HR 0.28 (95% CI: 0.11 to 0.77), p=0.013; subdistribution HR 0.32 (95% CI: 0.12 to 0.84), p=0.021). The use of SGLT2i was also associated with a higher overall survival (85.3% vs 63.0% at 2 years, p<0.001). The risk of serious adverse events such as hypoglycaemia and sepsis was similar between the two groups.ConclusionsThe use of SGLT2i was associated with a lower rate of incident HF and prolonged overall survival in patients with cancer with diabetes mellitus.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results